开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2020-08-16 ms4000001908142028

审稿速度:6.0 | 投稿命中率:25.0
经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！

784 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2023-04-22 晨曦呀来自浙江省

偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞
经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？

98 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2023-05-26 庸医小王来自湖北省

审稿速度:1.0 | 投稿命中率:95.0
经验分享：May 25, 2023 Submitted to Journal

111 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2021-11-23 ms4000000531440481

请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢

118 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2023-02-04 qyzhangsai 来自山东省

投稿命中率:50.0
经验分享：已经送审40天了，还没消息，还要等多久啊

106 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2022-11-01 12201bb7m09(暂无昵称)

偏重的研究方向：肥胖
经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？

108 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2019-06-26 石榴

审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。

202 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2021-12-29 衣谷

选刊时有哪些需要避免的雷区？

120 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2021-12-29 学医的彭于晏

哪些期刊是公认的水刊？

119 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：终于中了，大修修回二审11天，accept ！数据量大，形式审查严格，非常正规的杂志，口碑巨佳，非常respective！除了因子不高，其他都是远超综合类五六分，以及个别领域虚高因子的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=784, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向：细胞机制研究;代谢性疾病;中性粒细胞 经验分享：想问问大家，这个杂志审稿速度快嘛，现在的状态是Submitted to Journal。要交50美金才审嘛？怎么在投稿要求中没看见啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀，是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0 经验分享：已经送审40天了，还没消息，还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向：肥胖 经验分享：请问这个杂志一般邀请几个审稿人啊？我under review 2个礼拜后，审稿日期刷新了2次，请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快，直接小修然后接受。老牌病理杂志，有较高的声誉。我做的并不是纯病理，是与疾病相关的研究，药物治疗，有IHC等病理检测，感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

2019-10-23 1258c15em32暂无昵称

审稿速度:1.0 | 投稿命中率:25.0
经验分享：难度挺大的期刊，实验室之前投了几篇都悲剧了，后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了，很开心，就是分低了点。希望AJP能再现辉煌。

268 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务